Biovica’s DiviTum®TKa included in new UK breast cancer study
DiviTum®TKa has been selected to be included in a new prospective study of women with hormone receptor positive metastatic breast cancer. The aim of including DiviTum®TKa in the study is to investigate if this marker can be used for disease monitoring during treatment with a CDK4/6 inhibitor, which in combination with an aromatase inhibitor is considered standard of care for this subgroup of patients.
The hypothesis is that routine imaging can be delayed until predefined levels of biomarker progression is detected. The aim is to establish a biomarker algorithm, which includes DiviTum®TKa and other biomarkers, that safely can define response to therapy or stable disease and also predict disease progression. DiviTum®TKa accurately correlates with disease status and can be a useful tool in this respect.
“Our study aims to optimise the monitoring of patients, utilising circulating biomarkers to avoid unnecessary imaging exams. We have chosen to include DiviTum for analysis of TK activity as accurate measurements of cell proliferation rate is likely to be important in this setting. DiviTum has documented ability to provide precise prognostic and efficacy monitoring capabilities and we look forward to see results that can potentially enhance monitoring options in metastatic breast cancer”, said Dr. Sacha J. Howell, FRCP, PhD and Principal Investigator of the study.
The study will collect blood samples before treatment initiation and during therapy with the aim to include approximately 100 patients in the UK and Sweden.
“We look forward to collaborate with Christie Hospital in Manchester and other clinics in the study in UK and Sweden in this exciting study, where we believe the results can potentially contribute to a more personalised approach also regarding radiological follow-up for metastatic breast cancer patients”, said Anders Rylander, CEO of Biovica.
Link to study NCT04597580